Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection

Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection

Abstract Pulmonary hypertension (PH) complicates the treatment of interstitial lung disease (ILD) patients resulting in poor functional status and worse outcomes. Early recognition of PH in ILD is important for initiating therapy and considering lung transplantation. However, no standard exists rega...

Descripció completa

Dades bibliogràfiques
Autors principals:	Raj Parikh, Ippokratis Konstantinidis, David M. O'Sullivan, Harrison W. Farber
Format:	Article
Idioma:	English
Publicat:	Wiley 2022-10-01
Col·lecció:	Pulmonary Circulation
Matèries:	idiopathic pulmonary fibrosis interstitial lung disease prostacyclin pulmonary hypertension treprostinil
Accés en línia:	https://doi.org/10.1002/pul2.12141

Ítems similars

The PH‐ILD Detection tool: External validation and use in patients with ILD
per: Raj Parikh, et al.
Publicat: (2023-07-01)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
per: Julia McSweeney, et al.
Publicat: (2023-04-01)

Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil
per: Aparna C. Swaminathan, et al.
Publicat: (2024-11-01)

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
per: Jenna M. Faircloth, et al.
Publicat: (2023-03-01)

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration
per: Jenna M. Faircloth, et al.
Publicat: (2023-08-01)

The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil
per: Piotr Kędzierski, et al.
Publicat: (2025-01-01)

Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review
per: Abdullah A. Alqarni, et al.
Publicat: (2023-08-01)

Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing
per: Shelsey W. Johnson, et al.
Publicat: (2022-07-01)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
per: Nicholas S. Hill, et al.
Publicat: (2022-07-01)

Evolution of pulmonary hypertension in interstitial lung disease: a journey through past, present, and future
per: Ahmad Arslan, et al.
Publicat: (2024-01-01)

PAH-specific therapy for pulmonary hypertension and interstitial lung disease: A systemic review and meta-analysis
per: Ning Zhao, et al.
Publicat: (2022-11-01)

Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in a Prospective Registry of Interstitial Lung Diseases in Eastern Siberia
per: Maria S. Nashatyreva, et al.
Publicat: (2023-01-01)

Unexpected Acceleration in Treprostinil Delivery Administered by a Lenus Pro® Implantable Pump in Two Patients Treated for Pulmonary Arterial Hypertension
per: Garance Kopp, et al.
Publicat: (2020-10-01)

Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension
per: Kellie Morland, et al.
Publicat: (2021-10-01)

Interstitial Lung Abnormality in Asian Population
per: Gong Yong Jin
Publicat: (2024-04-01)

The application of metabolomics toward idiopathic pulmonary fibrosis and potential metabolomic value of diverse samples in interstitial lung diseases
per: Mingtao Liu, et al.
Publicat: (2023-09-01)

CLINICAL PROFILE OF INTERSTITIAL LUNG DISEASES CASES
per: Gagiya Ashok K, et al.
Publicat: (2012-03-01)

Converging Pathways: A Review of Pulmonary Hypertension in Interstitial Lung Disease
per: Alexandra Lawrence, et al.
Publicat: (2024-09-01)

Pulmonary Hypertension in Interstitial Lung Disease: Updates in Disease, Diagnosis, and Therapeutics
per: Zachary A. Haynes, et al.
Publicat: (2023-10-01)

Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report
per: E. A. Rezukhina, et al.
Publicat: (2021-09-01)

Interstitial lung diseases with progressive pulmonary fibrosis: pathogenetic features and approaches to therapy
per: N. A. Kuzubova, et al.
Publicat: (2020-11-01)

Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date
per: Cassady SJ, et al.
Publicat: (2024-06-01)

Osteopontin as a Biomarker in Interstitial Lung Diseases
per: David Iturbe-Fernández, et al.
Publicat: (2024-05-01)

Multidisciplinary discussion for diagnosis of interstitial lung disease in real life
per: Sabina Anna Guler, et al.
Publicat: (2016-05-01)

Increased expiratory flows identify early interstitial lung disease
per: Sami Mohammed Alyami, et al.
Publicat: (2023-01-01)

Role of Telomere Length in Survival of Patients with Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases
per: Sofía Tesolato, et al.
Publicat: (2023-12-01)

Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival
per: Jonathan Keow, et al.
Publicat: (2022-06-01)

Evaluation of progressive pulmonary fibrosis in non-idiopathic pulmonary fibrosis-interstitial lung diseases: a cross-sectional study
per: Özlem Erçen Diken, et al.
Publicat: (2024-08-01)

Estimation of plasmic concentration of the brain natriuretic peptide in interstitial pulmonary diseases with pulmonary hypertension: clinical role
per: N A Mukhin, et al.
Publicat: (2009-03-01)

Efficacy of oral treprostinil for treating pulmonary arterial hypertension: a systematic review and meta-analysis
per: Lianghua Xiao, et al.
Publicat: (2024-09-01)

Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management
per: Justin M. Oldham, et al.
Publicat: (2017-08-01)

Altered prostanoid production by fibroblasts cultured from the lungs of human subjects with idiopathic pulmonary fibrosis
per: Pierson Richard, et al.
Publicat: (2002-02-01)

Abnormal platelet aggregation in pediatric pulmonary hypertension
per: Stephanie S. Handler, et al.
Publicat: (2022-07-01)

Interstitial lung abnormalities in a large clinical lung cancer screening cohort: association with mortality and ILD diagnosis
per: Avignat S. Patel, et al.
Publicat: (2023-02-01)

Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases
per: Jia Liu, et al.
Publicat: (2024-04-01)

A Case of Interstitial Lung Disease-Related Pulmonary Hypertension Successfully Treated with Inhaled Iloprost
per: Ji Hoon Jang, et al.
Publicat: (2024-08-01)

An observational cohort study of interstitial lung abnormalities (ILAs) in a large Japanese health screening population (Kumamoto ILA study in Japan: KILA-J)
per: Kazuya Ichikado, et al.
Publicat: (2023-06-01)

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
per: Hardin EA, et al.
Publicat: (2016-11-01)

Noninvasive determinants of pulmonary hypertension in interstitial lung disease
per: Phillip Joseph, et al.
Publicat: (2023-01-01)

Pulmonary Hypertension in the Course of Interstitial Lung Diseases—A Personalised Approach Is Needed to Identify a Dominant Cause and Provide an Effective Therapy
per: Aneta Kacprzak, et al.
Publicat: (2023-07-01)